Author
P. Paparel
Also Known As
E. Xylinas, P Paparel, P. Paparel, P.P. Paparel, PHILIPPE PAPAREL, Paparel, P, Paparel, Philippe, Philippe PAPAREL, Philippe Paparel
260
Publications
3K
Citations
29
H-Index
64
Concepts
All Affiliations
| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Medicine | 20 | 29 | 1.4K |
2 | Engineering | 1 | 1 | 108 |
3 | Health Sciences | 1 | 1 | 16 |
4 | Public Health | 1 | 1 | 35 |
5 | Biostatistics | 1 | 1 | 35 |
P. Paparel
×
58
Publications
2.2K
Citations
26
H-Index
| Year | Citations | |
|---|---|---|
2008 | 229 | |
2018 | 138 | |
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial Yann Vano, Réza Elaidi, Mostefa Bennamoun, UrologyOncologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor | 2022 | 128 |
2013 | 108 | |
2011 | 99 | |
2006 | 95 | |
2016 | 86 | |
2019 | 69 | |
2008 | 68 | |
2006 | 62 |
Page 1
Page 1